Comparison between single and dual therapy with drugs that inhibits platelet aggregation in patient undergoing the percutaneous left atrial appenDAge closure (ARMYDA-AMULET in which people will be allocated by chance to receive two different options of treatment and which will involves different clinical sites)

Prior treatment

• Major surgery within one month
• Fibrinolytic therapy within 10 days
• Requirement for on-going therapy with clopidogrel at the time of screening evaluation (e.g. current therapy with clopidogrel at the time of the screening evaluation will be an exclusion criterion)
• Planned oral anticoagulant therapy after the procedure

Other illness

• Myocardial infarction or percutaneous coronary intervention <6 months
• Recent stroke (<1 month)
• Known hypersensitivity to the study drugs (aspirin or clopidogrel)
• Patients deemed to be unsuitable for at least 6 months antiplatelet therapy (SAPT or DAPT) because of a recent (<1 month) major bleeding event
• Mechanical heart prosthetic valve
• Active bleeding

Lab values

• Platelet count <50,000/µL
• Baseline hemoglobin <9 g/dL

Other

• CHADS-VAsc score 0-1
• Intracranial neoplasm, aneurysm or arterio-venous malformation
• Pregnant woman
• Breast-feeding
• Donne fertili impossibilitate ad utilizzare contraccettivi durante lo studio
• Moderate to severe mitral stenosis
• Active endocarditis

• Men or women aged =18 years signing a specific informed consent
• Patients with a planned percutaneous LAA closure
• Patients with documented non-valvular AF, irrespective of the type (paroxysmal, permanent, persistent), and CHA2DS2-VASc score =2
• Patients suitable for treatment with aspirin and clopidogrel according to the Summaries of product characteristics (SmPCs)
• Patients considered unsuitable for long-term oral anticoagulant therapy due to a high bleeding risk. Patients will be judged unsuitable for anticoagulation because of bleeding-prone comorbidities, history of previous bleeding (with or without anticoagulant treatment) or an expected low adherence to therapy
• Patient’s availability to undergo the follow-up visits scheduled for the study
• Negative pregnancy testing (if applicable), performed at the time of enrollment